Department of Neurology, Cognition and Aging Center, Kaohsiung Chang Gung Memorial Hospital, Chang Gung University College of Medicine, No. 123 Ta-Pei Road, Niaosung, Kaohsiung County, 833, Taiwan.
Psychiatric Department, Taipei Veterans General Hospital, Taipei, Taiwan.
Alzheimers Res Ther. 2018 Feb 8;10(1):17. doi: 10.1186/s13195-018-0344-4.
Alzheimer's disease (AD) is a complex neurodegenerative disease, and genetic differences may mediate neuronal degeneration. In humans, a single-nucleotide polymorphism in the B-cell chronic lymphocytic leukemia/lymphoma-2 (Bcl-2) gene, rs956572, has been found to significantly modulate Bcl-2 protein expression in the brain. The Bcl-2 AA genotype has been associated with reduced Bcl-2 levels and lower gray matter volume in healthy populations. We hypothesized that different Bcl-2 genotype groups may modulate large-scale brain networks that determine neurobehavioral test scores.
Gray matter structural covariance networks (SCNs) were constructed in 104 patients with AD using T1-weighted magnetic resonance imaging with seed-based correlation analysis. The patients were stratified into two genotype groups on the basis of Bcl-2 expression (G carriers, n = 76; A homozygotes, n = 28). Four SCNs characteristic of AD were constructed from seeds in the default mode network, salience network, and executive control network, and cognitive test scores served as the major outcome factor.
For the G carriers, influences of the SCNs were observed mostly in the default mode network, of which the peak clusters anchored by the posterior cingulate cortex seed determined the cognitive test scores. In contrast, genetic influences in the A homozygotes were found mainly in the executive control network, and both the dorsolateral prefrontal cortex seed and the interconnected peak clusters were correlated with the clinical scores. Despite a small number of cases, the A homozygotes showed greater covariance strength than the G carriers among all four SCNs.
Our results suggest that the Bcl-2 rs956572 polymorphism is associated with different strengths of structural covariance in AD that determine clinical outcomes. The greater covariance strength in the four SCNs shown in the A homozygotes suggests that different Bcl-2 polymorphisms play different modulatory roles.
阿尔茨海默病(AD)是一种复杂的神经退行性疾病,遗传差异可能介导神经元变性。在人类中,B 细胞慢性淋巴细胞白血病/淋巴瘤-2(Bcl-2)基因中的单核苷酸多态性 rs956572 已被发现可显著调节大脑中的 Bcl-2 蛋白表达。Bcl-2AA 基因型与健康人群中 Bcl-2 水平降低和灰质体积降低有关。我们假设不同的 Bcl-2 基因型组可能调节决定神经行为测试评分的大规模大脑网络。
使用基于种子的相关分析,对 104 例 AD 患者的 T1 加权磁共振成像进行分析,构建灰质结构协方差网络(SCN)。根据 Bcl-2 表达将患者分为两组(G 携带者,n=76;A 纯合子,n=28)。从默认模式网络、突显网络和执行控制网络中的种子构建了四个 AD 特征 SCN,认知测试评分作为主要的结果因素。
对于 G 携带者,SCN 的影响主要在默认模式网络中观察到,其由后扣带回皮质种子锚定的峰值簇决定认知测试评分。相比之下,在 A 纯合子中,遗传影响主要在执行控制网络中发现,并且背外侧前额叶皮质种子和相互连接的峰值簇都与临床评分相关。尽管病例数较少,但在所有四个 SCN 中,A 纯合子的协方差强度均大于 G 携带者。
我们的结果表明,Bcl-2 rs956572 多态性与 AD 中决定临床结果的不同结构协方差强度相关。在 A 纯合子中,四个 SCN 中显示出的更大的协方差强度表明不同的 Bcl-2 多态性发挥不同的调节作用。